IOVA
IOVANCE BIOTHERAPEUTICS, INC.Company Information
- Company Name
- IOVANCE BIOTHERAPEUTICS, INC.
- CIK
- CIK0001425205
- Category
- Accelerated filer
- Ticker: Exchange
- IOVA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- IOVA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-06-05
- Last sale
- 2024-11-12
- Shares purchased (TTM)
- 60,600
- Shares sold (TTM)
- 50,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 280,856,356
- Shares outstanding
- 450,189,000
- Ownership
- 62.39%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 28.99%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 111 | 197 | 163 | 158 | 132 | 172 | 116 | 164 | 229 | 134 | 115 | 268 | ||||||
| Restricted Cash Current | - | - | - | - | - | 1 | - | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 102 | 82 | 82 | 67 | 60 | 71 | 69 | - | - | 0 | 0 | - | ||||||
| Short Term Investments | 187 | 117 | 134 | 143 | 169 | 188 | 208 | - | - | 222 | 165 | 94 | ||||||
| Inventory Net | 56 | 58 | 52 | 52 | 50 | 66 | 52 | - | - | 18 | 10 | 9 | ||||||
| Prepaid Expense And Other Assets Current | 9 | 13 | 12 | 10 | 12 | 16 | 12 | - | - | 11 | 17 | 12 | ||||||
| Assets Current | 464 | 467 | 443 | 429 | 423 | 513 | 457 | - | - | 386 | 308 | 383 | ||||||
| Property Plant And Equipment Net | 131 | 131 | 131 | 127 | 122 | 112 | 109 | - | - | 112 | 114 | 113 | ||||||
| Finite Lived Intangible Assets Net | 264 | 269 | 279 | 285 | 296 | 285 | 282 | - | - | 294 | 229 | 224 | ||||||
| Operating Lease Right Of Use Asset | 43 | 44 | 46 | 49 | 50 | 51 | 55 | - | - | 72 | 63 | 66 | ||||||
| Restricted Cash | - | - | - | - | - | - | - | - | - | 6 | 66 | 66 | ||||||
| Restricted Cash Noncurrent | 6 | 6 | 6 | 6 | 6 | 6 | 6 | - | - | - | 66 | - | ||||||
| Other Assets Noncurrent | 6 | 8 | 8 | 9 | 10 | 0 | 0 | - | - | 0 | 0 | 0 | ||||||
| Assets | 916 | 926 | 913 | 905 | 907 | 967 | 910 | - | - | 870 | 780 | 852 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | 46 | 69 | 61 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 26 | 37 | 22 | 31 | 32 | 28 | 28 | - | - | 26 | 33 | 19 | ||||||
| Accrued Liabilities And Other Liabilities | 78 | 88 | 111 | 87 | 89 | 85 | 82 | - | - | - | 69 | - | ||||||
| Notes Payable Current | - | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 3 | 3 | 4 | 6 | 7 | 8 | 13 | - | - | 11 | 8 | 10 | ||||||
| Liabilities Current | 107 | 129 | 138 | 126 | 129 | 123 | 122 | - | - | 83 | 110 | 91 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 43 | 44 | 44 | 45 | 45 | 44 | 44 | - | - | 72 | 67 | 68 | ||||||
| Deferred Income Tax Liabilities Net | 29 | 31 | 32 | 32 | 35 | 32 | 32 | - | - | 33 | 17 | 18 | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | 1 | - | - | 1 | 1 | 1 | ||||||
| Liabilities Noncurrent | 73 | 74 | 76 | 77 | 80 | 76 | 78 | - | - | 107 | 85 | 87 | ||||||
| Liabilities | 179 | 204 | 215 | 203 | 209 | 199 | 200 | - | - | 190 | 196 | 178 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 13 | 13 | 16 | 16 | 21 | 6 | -1 | - | - | 0 | 3 | -9 | ||||||
| Additional Paid In Capital | 3,625 | 3,564 | 3,458 | 3,390 | 3,290 | 3,262 | 3,096 | - | - | 2,805 | 2,594 | 2,579 | ||||||
| Retained Earnings Accumulated Deficit | -2,902 | -2,855 | -2,776 | -2,704 | -2,612 | -2,501 | -2,385 | - | - | -2,125 | -2,012 | -1,896 | ||||||
| Stockholders Equity | 736 | 722 | 699 | 702 | 698 | 768 | 710 | 773 | 769 | 680 | 585 | 674 | ||||||
| Liabilities And Stockholders Equity | 916 | 926 | 913 | 905 | 907 | 967 | 910 | - | - | 870 | 780 | 852 | ||||||
| Series A Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Series B Preferred Stock | 0 | 2 | 2 | 0 | 0 | 2 | 3 | 0 | 0 | 3 | 3 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 650 | 500 | 500 | 500 | 500 | 500 | 500 | - | - | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 453 | 438 | 412 | 385 | 342 | 334 | 305 | - | - | 280 | 256 | 256 | ||||||
| Shares Outstanding | 453 | 438 | 412 | 385 | 342 | 334 | 305 | - | - | 280 | 256 | 256 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialIOVANCE BIOTHERAPEUTICS, INC. (IOVA) — SEC Financial Statements & Analysis
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) is a biological products, (no diagnostic substances) company, incorporated in DE. IOVANCE BIOTHERAPEUTICS, INC. trades on Nasdaq as: IOVA. IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, IOVANCE BIOTHERAPEUTICS, INC. carries a market cap of $1.87B, a P/E ratio of -6.47x, a P/B ratio of 2.54x, a P/S ratio of 5.76x, an enterprise value of $1.76B, and an EV/EBITDA multiple of -6.10x. On profitability, it posts a gross margin of 48.40%, an operating margin of -92.72%, a net margin of -89.09%, a Return on Equity (ROE) of -40.36%, a Return on Assets (ROA) of -31.76%, and a Return on Invested Capital (ROIC) of -50.57%. Per share, it reports EPS of $-0.64, diluted EPS of $-0.64, free cash flow per share of $-0.66, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 34.55% year-over-year, net income growth of -25.75% year-over-year, and EPS growth of -44.83% year-over-year. On the balance sheet, it maintains a current ratio of 4.35x, a quick ratio of 3.74x, working capital of $357.41M, a debt-to-equity ratio of 0.24x, a debt ratio of 0.2, free cash flow of $-296.39M (TTM), and net debt of $-116.77M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.87B
- P/E TTM
- -6.47x
- EPS TTM
- $-0.64
- P/B TTM
- 2.54x
- ROE TTM
- -40.36%
- ROA TTM
- -31.76%
- Debt To Equity
- 0.24x
- Free Cash Flow TTM
- $-296.39M
- Net Revenue TTM Growth 1Y
- 34.55%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is IOVANCE BIOTHERAPEUTICS, INC. in?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does IOVA trade on?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) trades on the Nasdaq.
Where is IOVANCE BIOTHERAPEUTICS, INC. incorporated?
IOVANCE BIOTHERAPEUTICS, INC. is incorporated in DE.
When was IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s most recent SEC filing?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is IOVA's market cap?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has a market capitalization of $1.87B as of 2026-06-30.
What is IOVA's EPS (earnings per share)?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s trailing twelve month EPS is $-0.64 as of 2026-06-30.
What is IOVA's ROE (return on equity)?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s trailing twelve month Return on Equity (ROE) is -40.36% as of 2026-06-30.
What is IOVA's ROA (return on assets)?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s trailing twelve month Return on Assets (ROA) is -31.76% as of 2026-06-30.
What is IOVA's ROIC (return on invested capital)?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s trailing twelve month Return on Invested Capital (ROIC) is -50.57% as of 2026-06-30.
What is IOVA's EV/EBITDA?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s trailing twelve month EV/EBITDA is -6.10x as of 2026-06-30.